|
1 February Epidemiology and Spectrum of RSV Disease
3pm (GMT) Chair: Dr Natasha Halasa, Vanderbilt University Medical Center, USA
|
|
Keynote Presentation:
RSV Epidemiology in a Changing World
Chair of Paediatric Infectious Diseases and Global Health
Centre for Global Health, Usher Institute
The University of Edinburgh, UK
(30 min presentation - includes 5 min for Q&A)
The impact of respiratory syncytial virus (RSV) on mortality and hospitalizations in Hong Kong, 1998-2015
Xiong Qian | University of Hong Kong, Hong Kong (15min)
Early life severe respiratory syncytial virus infection increased the risk of asthma later in life Maarten van Wijhe | Statens Serum Institut, Denmark (15min)
The Clinical Characteristics, Severity, and Seasonality of RSV Subtypes among Hospitalized Jordanian Children
Ahmad Yanis | Vanderbilt University Medical Center, Nashville, USA (15min)
Maternal and family social risk factors for early life respiratory syncytial virus (RSV)-related hospitalizations
Tiffany Fitzpatrick | Yale School of Public Health, New Haven, USA (15min)
|
|
8 February RSV Molecular Biology
3pm (GMT) Chair: Prof Ultan Power, Queens University Belfast, UK
|
|
Keynote Presentation:
Insights into the generation and function of defective viral genomes during RSV infection
Prof Carolina Lopez
BJC Investigator / Lopez Lab
Department of Molecular Biology
Washington University School of Medicine in St. Louis, USA
(30 min presentation - includes 5 min for Q&A)
Optimized reverse genetics systems for clinical isolates of respiratory syncytial virus ON1 and BA9 strains enables rapid evaluation of naturally occurring antibody escape mutants
Martin Ludlow | University of Veterinary Medicine Hannover Foundation, Hannover, Germany (15min)
Trimerization of the RSV Fusion protein leads to a high energy prefusion state, or why trimerizing is destabilizing RSV F
Johannes Langedijk | Janssen Vaccines & Prevention, The Netherlands (15min)
The respiratory syncytial virus attachment glycoprotein is altered when produced in primary human bronchial epithelial cultures, reducing its infectivity for cell lines
Tiffany King | The Ohio State University / Nationwide Childrens Hospital, USA (15min)
An unexpected encounter: RSV-NS1 interacts with a member of the mediator complex
Tessa Van Royen | VIB-UGent Center for Medical Biotechnology, Ghent University, Belgium (15min)
|
|
15 February RSV Pathogenesis and Immunity
3pm (GMT) Chair: Dr Lindsay Broadbent, Queens University Belfast, UK
|
|
Keynote Presentation:
An integrated view of susceptibility and resistance to RSV disease
Prof Peter Openshaw
Department of Experimental Medicine
Imperial College London, UK
(30 min presentation - includes 5 min for Q&A)
Localization of Respiratory Syncytial Virus (RSV) Antigen in Bronchiolar Epithelium
Mark Ackermann | LambCure LLC and Oregon State University, USA (15min)
Influenza Virus Inhibits RSV Infection via a Two-wave Expression of IFIT Proteins
Michal Mandelboim | Sheba Medical Center, Ramat Gan, Israel (15min)
Characterizing RSV Immunity on Mucosal Surfaces Following Natural Infection
Peter F. Wright | Geisel School of Medicine at Dartmouth, Hanover, USA (15min)
Presented by co-author Meave Otieno
Immunological impact of age in an experimental RSV challenge model in elderly humans
Stephanie Ascough | Imperial College London, UK (15min)
|
|
22 February RSV Vaccines and Therapies
3pm (GMT) Chair: Dr Simon B. Drysdale, St George's Hospital, London, UK
|
|
Keynote Presentation:
Update on RSV Vaccines
Dr Barney S. Graham
Deputy Director
Vaccine Research Center
National Institute of Allergy and Infectious Diseases, USA
(30 min presentation - includes 5 min for Q&A)
A Single-cycle Live RSV Vaccine Expressing Prefusion F Protein
Pramila Lamichhane | Oklahoma State University, USA (15min)
Phase 1/2a Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Seropositive Toddlers Aged 12 -24 Months
Matthew Snape | University of Oxford, UK (15min)
The Sensitivity of Palivizumab Cost-effectiveness in Mali to Case Fatality Estimates
Amanda Driscoll | University of Maryland, Baltimore, USA (15min)
The Flavonoid Cyanidin Shows Antiviral and Immunomodulatory Properties Against RSV, in Vitro and in Vivo
Carlos Bueno | Universidad de Buenos Aires, Argentina (15min)
|
| |
|
